EICHORPublic-registry site landscape for NCT06712836, “A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight”, a Obesity study sponsored by Pfizer. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06712836 (registry record) |
| Study title | A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight |
| Official title | A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of 28 Weeks to Investigate the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight Followed by a 32-Week Extension (VESPER-1) |
| Sponsor | Pfizer |
| Condition(s) | Obesity; Overweight or Obesity |
| Phase | PHASE2 |
| Listed sites | 2 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT06712836.
Eichor generates a preliminary site-risk snapshot for NCT06712836 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Obesity trials
More from Pfizer
← Eichor home · All tracked trials · Obesity studies · Weekly briefs
